Palatin Technologies (NYSE:PTN) Earns Sell Rating from Analysts at StockNews.com

Posted by on May 15th, 2025

StockNews.com began coverage on shares of Palatin Technologies (NYSE:PTN – Free Report) in a research report sent to investors on Monday. The brokerage issued a sell rating on the stock.

Palatin Technologies Price Performance

Shares of PTN opened at $0.09 on Monday. The company has a market cap of $2.45 million, a PE ratio of -0.06 and a beta of 0.94. Palatin Technologies has a twelve month low of $0.09 and a twelve month high of $2.48.

Palatin Technologies Company Profile

(Get Free Report)

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.

Read More

Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.